Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytochrome b-245 beta chain, commonly known as NOX2 or gp91phox, is the catalytic, membrane-spanning subunit of the phagocyte NADPH oxidase complex [1, 4, 6]. Its primary biological function is to transfer electrons from NADPH to molecular oxygen, generating superoxide radicals and other reactive oxygen species (ROS) essential for the microbicidal activity of phagocytes like neutrophils and macrophages [5, 9, 10]. Mutations in the CYBB gene, which encodes this protein, lead to X-linked Chronic Granulomatous Disease (CGD), a condition characterized by a severely compromised immune system and recurrent life-threatening infections [1, 5, 14]. Conversely, excessive NOX2 activity and the resulting oxidative stress are implicated in the pathogenesis of various chronic conditions, including atherosclerosis, hypertension, neurodegenerative diseases, and chronic inflammation [3, 6, 9]. Consequently, NOX2 has emerged as a significant therapeutic target, with small-molecule inhibitors like GSK2795039 being developed to mitigate oxidative damage in these diseases [3, 7, 9]. However, therapeutic inhibition of NOX2 carries the risk of inducing a transient CGD-like state, potentially increasing patient susceptibility to infections [3, 10].
Inhibition of the NADPH oxidase complex to prevent the transfer of electrons from NADPH to molecular oxygen, thereby reducing the production of superoxide and other reactive oxygen species (ROS).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytochrome b-245 beta chain (NOX2) (NOX2).